NCT00905541

Brief Summary

3-Hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) decrease apolipoprotein B-100-containing lipoproteins by increasing their fractional catabolic rates through low-density lipoproteins (LDL) receptor-mediated uptake. Their influence on hepatic secretion of these lipoproteins is controversial. The current study investigates whether simvastatin influences lipoprotein secretion.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 1998

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 1998

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 1999

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2000

Completed
9.2 years until next milestone

First Submitted

Initial submission to the registry

May 18, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 20, 2009

Completed
Last Updated

May 20, 2009

Status Verified

May 1, 2009

Enrollment Period

4 months

First QC Date

May 18, 2009

Last Update Submit

May 18, 2009

Conditions

Outcome Measures

Primary Outcomes (1)

  • apoB-100 kinetic parameters

    One year

Secondary Outcomes (1)

  • Lipoprotein concentrations

    One year

Study Arms (3)

No treatment

NO INTERVENTION

Phase A: No treatment

simvastatin chronic

EXPERIMENTAL

Phase B: 40 mg/day simvastatin

Drug: simvastatin

simvastatin acute-on-chronic

EXPERIMENTAL

Phase C: 80 mg simvastatin acute-on-chronic

Drug: simvastatin

Interventions

40 mg/day

simvastatin chronic

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Hypercholesterolemia

You may not qualify if:

  • Obesity
  • Treatment with lipid-lowering drugs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Bonn

Bonn, Germany

Location

MeSH Terms

Conditions

Hypercholesterolemia

Interventions

Simvastatin

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

LovastatinNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic Compounds

Study Officials

  • Heiner K. Berthold, MD, PhD

    University of Bonn

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 18, 2009

First Posted

May 20, 2009

Study Start

November 1, 1998

Primary Completion

March 1, 1999

Study Completion

March 1, 2000

Last Updated

May 20, 2009

Record last verified: 2009-05

Locations